Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Gilead Sciences Announces Third Quarter 2022 Financial Results

Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion

Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion

Oncology Sales Increased 79% Year-Over-Year to $578 million

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022.

Chairman and Chief Executive Officer of Gilead Sciences, Daniel O’Day said: “This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy in treatment, and we received our first approval for our long-acting HIV agent, lenacapavir, in Europe. In oncology, there is increasing demand for cell therapies and Trodelvy. Yescarta and Tecartus received two approvals in Europe and Trodelvy was granted FDA Priority Review for HR+/HER2- metastatic breast cancer. Overall, we are seeing terrific progress from a commercial and clinical perspective and look forward to building on this momentum.”

Third Quarter 2022 Financial Results

  • Total third quarter 2022 revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and oncology products.
  • Diluted Earnings Per Share (“EPS”) decreased to $1.42 for the third quarter of 2022 compared to $2.05 for the same period in 2021, mainly driven by higher acquired in-process research and development (“IPR&D”) expenses of $389 million primarily due to the acquisition of MiroBio Ltd. (“MiroBio”) and lower product gross margin and revenues, partially offset by lower income tax expense.
  • Non-GAAP diluted EPS decreased to $1.90 for the third quarter of 2022 compared to $2.65 for the same period in 2021, primarily driven by the MiroBio acquisition, as well as lower product gross margin and revenues.
  • As of September 30, 2022, Gilead had $6.9 billion of cash, cash equivalents and marketable debt securities down from $7.8 billion as of December 31, 2021.
  • During the third quarter of 2022, Gilead generated $2.9 billion in operating cash flow.
  • During the third quarter of 2022, Gilead repaid $1.0 billion of debt, made a cash payment of $414 million to acquire MiroBio, paid dividends of $928 million and repurchased $180 million of common stock.

Product Sales Performance

Total third quarter 2022 product sales decreased 5% to $7.0 billion compared to the same period in 2021. Total product sales, excluding Veklury, increased 11% to $6.1 billion in the third quarter of 2022 compared to the same period in 2021, primarily due to increased product sales related to HIV, cell therapy, hepatitis C virus (“HCV”) and Trodelvy® (sacituzumab govitecan-hziy).

HIV product sales increased 7% to $4.5 billion in the third quarter of 2022 compared to the same period in 2021, primarily driven by favorable channel mix associated with government utilization leading to higher average realized price, as well as higher demand.

  • Biktarvy® (bictegravir 50mg/emtricitabine 200mg (“FTC”)/tenofovir alafenamide 25mg (“TAF”)) sales increased 22% year-over-year in the third quarter of 2022, primarily due to higher demand and channel mix.
  • Descovy® (FTC 200mg/TAF 25mg) sales increased 16% year-over-year in the third quarter of 2022, primarily driven by channel mix and higher demand, partially offset by inventory dynamics.

HCV product sales increased 22% to $524 million in the third quarter of 2022 compared to the same period in 2021, primarily due to a favorable resolution of a prior year rebate claim in Europe and other favorable pricing dynamics in the United States, partially offset by fewer patient starts.

Hepatitis B virus (“HBV”) and hepatitis delta virus (“HDV”) product sales increased 7% to $264 million in the third quarter of 2022 compared to the same period in 2021, primarily driven by Vemlidy® (TAF 25mg). Vemlidy sales increased 10% in the third quarter of 2022 compared to the same period in 2021, primarily driven by favorable inventory dynamics.

Cell therapy product sales increased 79% to $398 million in the third quarter of 2022 compared to the same period in 2021.

  • Yescarta® (axicabtagene ciloleucel) sales increased 81% to $317 million in the third quarter of 2022, primarily driven by demand in relapsed or refractory (“R/R”) large B-cell lymphoma (“LBCL”) in the United States and Europe.
  • Tecartus® (brexucabtagene autoleucel) sales increased 72% to $81 million in the third quarter of 2022, primarily driven by demand in R/R mantle cell lymphoma (“MCL”) in the United States and Europe as well as in adult R/R B-cell precursor acute lymphoblastic leukemia (“ALL”) in the United States.

Trodelvy sales increased by 78% to $180 million in the third quarter of 2022 compared to the same period in 2021, primarily driven by adoption in both the second- and third-line settings for the treatment of metastatic triple-negative breast cancer.

Veklury sales decreased by 52% to $925 million for the third quarter of 2022 compared to the same period in 2021, primarily driven by lower rates of COVID-19 related hospitalizations compared to the third quarter of 2021. Veklury revenue generally reflects COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19.

Third Quarter 2022 Product Gross Margin, Operating Expenses and Effective Tax Rate

  • Product gross margin was 80.0% for the third quarter of 2022 compared to 83.4% for the same period in 2021. Non-GAAP product gross margin was 86.8% for the third quarter of 2022 compared to 90.0% in the same period in 2021. The decreases were primarily driven by a favorable court decision in the third quarter of 2021 that led to the reversal of the previously recorded $175 million litigation reserve during that period, as well as Biktarvy-related royalty expense that began in the first quarter of 2022 and a change in product mix.
  • Research and development (“R&D”) expenses for the third quarter of 2022 were $1.1 billion, relatively flat with the same period in 2021. Non-GAAP R&D expenses for the third quarter of 2022 were $1.2 billion, relatively flat with the same period in 2021(1).
  • Acquired IPR&D expenses for the third quarter of 2022 were $448 million compared to $65 million(1) in the same period in 2021. The increase primarily reflects an expense of $389 million related to the MiroBio acquisition.
  • Selling, general and administrative (“SG&A”) expenses for the third quarter of 2022 were $1.2 billion, relatively flat with the same period in 2021. Non-GAAP SG&A expenses for the third quarter of 2022 were $1.2 billion, relatively flat with the same period in 2021.
  • The effective tax rate (“ETR”) for the third quarter of 2022 was 26.6% compared to 24.8% for the same period in 2021. Non-GAAP ETR for the third quarter of 2022 was 22.4% compared to 18.9% for the same period in 2021. The increases in GAAP and Non-GAAP ETR were primarily due to a non-deductible acquired IPR&D charge related to Gilead’s acquisition of MiroBio.

________________________________

(1)

Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from R&D expenses to Acquired IPR&D expenses in the Condensed Consolidated Statements of Income. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire IPR&D projects. Prior periods have been recast for both GAAP and Non-GAAP reporting to reflect this classification, resulting in a reduction of previously-reported R&D expenses of $46 million and $93 million for the three and nine months ended September 30, 2021, respectively, and $8 million for the three months ended March 31, 2022.

Guidance and Outlook

For the full-year, Gilead has updated its guidance and now expects:

  • Total product sales between $25.9 billion and $26.2 billion, compared to $24.5 billion and $25.0 billion previously.
  • Total product sales, excluding Veklury, between $22.5 billion to $22.8 billion, compared to $22.0 billion and $22.5 billion previously.
  • Total Veklury sales of approximately $3.4 billion, compared to approximately $2.5 billion previously.
  • Non-GAAP earnings per share between $6.95 and $7.15, compared to $6.35 and $6.75 previously.
  • Earnings per share between $3.35 and $3.55, compared to $2.90 and $3.30 previously.

This financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. A reconciliation between GAAP and non-GAAP financial information for the 2022 guidance is provided in the accompanying tables. Also see the Forward-Looking Statements described below. The financial guidance is subject to a number of risks and uncertainties, including uncertainty around the duration and magnitude of the COVID-19 pandemic. While the pandemic can be expected to continue to impact Gilead’s business and broader market dynamics, the rate and degree of these impacts as well as the corresponding recovery from the pandemic may vary across Gilead’s business.

Key Updates Since Our Last Quarterly Release

Virology

  • Announced the European Commission (“EC”) has granted Marketing Authorization for Sunlenca® (lenacapavir) for the treatment of HIV infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive antiviral regimen.
  • Announced that Merck & Co., Inc. (“Merck”) and Gilead plan to resume their Phase 2 study under an amended protocol. The study will evaluate an investigational once-weekly oral combination treatment regimen of Merck’s islatravir at a lower weekly dose and Gilead’s lenacapavir.
  • Received a positive opinion from EMA’s Committee for Medicinal Products for Human Use (“CHMP”) to expand the indication of Biktarvy to include pediatric patients with HIV who are at least 2 years of age and weigh at least 14 kg.
  • Received a positive opinion from EMA’s CHMP to extend the indication of Veklury for the treatment of pediatric patients under 12 years of age with COVID-19.
  • Announced that the World Health Organization has updated its living treatment guideline to conditionally recommend Veklury for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.
  • Demonstrated in vitro antiviral activity of Veklury against Omicron subvariants BA.2.12.1, BA.4 and BA.5, which are currently the most common circulating variants. Results confirm that Veklury retains antiviral activity against all Omicron subvariants analyzed to date.

Oncology

  • Presented results of the second interim analysis of the TROPiCS-02 study in patients with pre-treated HR+/HER2- metastatic breast cancer at the European Society for Medical Oncology meeting. The results demonstrated a statistically significant and clinically meaningful improvement in median overall survival (“OS”) as compared to chemotherapy (median OS: 14.4 months vs. 11.2 months; hazard ratio=0.79; 95% confidence interval: 0.65-0.96; p=0.02). Additionally, data from a post hoc subgroup analysis of TROPiCS-02 were presented that showed progression-free survival benefit in patients with HR+/HER2- metastatic breast cancer regardless of their HER2- status, consistent with the study’s intention-to-treat population.
  • Announced FDA accepted for Priority Review the supplemental Biologics License Application of Trodelvy for the treatment of patients with pre-treated HR+/HER2- metastatic breast cancer. Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer, and its safety and efficacy have not been established for this indication.
  • Announced an agreement to acquire the remaining worldwide development and commercialization rights to Trodelvy from Everest Medicines in Greater China, South Korea and other Asian markets.
  • Received European Marketing Authorization for Yescarta use in adults with second-line diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Additionally, the EC granted Marketing Authorization for Tecartus for the treatment of adult R/R ALL, and in Canada, received conditional marketing authorization for Yescarta for R/R follicular lymphoma after two or more lines of systemic therapy.
  • Received FDA approval of viral vector manufacturing facility in Oceanside, California.
  • Granted Orphan Drug Designation by FDA for KITE-222, an investigational CAR T-cell therapy targeted at C-type lectin-like molecule-1 (CLL-1), for the treatment of acute myeloid leukemia.
  • Announced strategic collaboration with MacroGenics, Inc. (“MacroGenics”) to develop bispecific antibodies to treat various cancers. The agreement includes an upfront payment of $60 million to MacroGenics and an exclusive option on MGD024, an investigational CD123 and CD3 bispecific antibody.

Inflammation

  • Completed the acquisition of MiroBio for $414 million in cash. MiroBio is a UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Corporate

  • Announced that the company’s Board of Directors declared a quarterly dividend of $0.73 per share of common stock for the fourth quarter of 2022. The dividend is payable on December 29, 2022, to stockholders of record at the close of business on December 15, 2022. Future dividends will be subject to Board approval.

Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

Conference Call

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

Non-GAAP Financial Information

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges, and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (“SEC”), Gilead no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales and Gilead’s ability to effectively manage the global supply and distribution of Veklury; Gilead’s ability to achieve its anticipated full year 2022 financial results, including as a result of potential adverse revenue impacts from COVID-19 and potential revenues from Veklury; Gilead’s ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangement with Dragonfly; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Trodelvy, Tecartus, Yescarta and bulevirtide, and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive regulatory approvals in a timely manner or at all, including FDA approval of lenacapavir for treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection, EC approval of lenacapavir for treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, EC approval of Veklury for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen and EC approval for Tecartus for the treatment of adult patients 26 years of age and above with R/R B-cell precursor ALL, and the risk that any such approvals, if granted, may be subject to significant limitations on use; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products, including the risk that Kite may be unable to increase its manufacturing capacity, timely manufacture and deliver its products or produce an amount of supply sufficient to satisfy demand for such products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products, including Yescarta; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2022 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

# # #

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. This report may also refer to trademarks, service marks and trade names of other companies.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions, except per share amounts)

 

2022

 

2021

 

2022

 

2021

Revenues:

 

 

 

 

 

 

 

 

Product sales

 

$

6,978

 

 

$

7,356

 

 

$

19,650

 

 

$

19,848

 

Royalty, contract and other revenues

 

 

64

 

 

 

65

 

 

 

242

 

 

 

213

 

Total revenues

 

 

7,042

 

 

 

7,421

 

 

 

19,892

 

 

 

20,061

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

1,395

 

 

 

1,223

 

 

 

4,261

 

 

 

3,974

 

Research and development expenses

 

 

1,149

 

 

 

1,101

 

 

 

3,429

 

 

 

3,243

 

Acquired in-process research and development expenses

 

 

448

 

 

 

65

 

 

 

786

 

 

 

270

 

In-process research and development impairment

 

 

 

 

 

 

 

 

2,700

 

 

 

 

Selling, general and administrative expenses

 

 

1,213

 

 

 

1,190

 

 

 

3,653

 

 

 

3,596

 

Total costs and expenses

 

 

4,205

 

 

 

3,579

 

 

 

14,829

 

 

 

11,083

 

Income from operations

 

 

2,837

 

 

 

3,842

 

 

 

5,063

 

 

 

8,978

 

Interest expense

 

 

(229

)

 

 

(250

)

 

 

(709

)

 

 

(763

)

Other income (expense), net

 

 

(176

)

 

 

(154

)

 

 

(571

)

 

 

(696

)

Income before income taxes

 

 

2,432

 

 

 

3,438

 

 

 

3,783

 

 

 

7,519

 

Income tax expense

 

 

(646

)

 

 

(852

)

 

 

(850

)

 

 

(1,694

)

Net income

 

 

1,786

 

 

 

2,586

 

 

 

2,933

 

 

 

5,825

 

Net loss attributable to noncontrolling interest

 

 

3

 

 

 

6

 

 

 

19

 

 

 

18

 

Net income attributable to Gilead

 

$

1,789

 

 

$

2,592

 

 

$

2,952

 

 

$

5,843

 

Net income per share attributable to Gilead common stockholders - basic

 

$

1.43

 

 

$

2.06

 

 

$

2.35

 

 

$

4.65

 

Shares used in per share calculation - basic

 

 

1,255

 

 

 

1,256

 

 

 

1,255

 

 

 

1,256

 

Net income per share attributable to Gilead common stockholders - diluted

 

$

1.42

 

 

$

2.05

 

 

$

2.34

 

 

$

4.63

 

Shares used in per share calculation - diluted

 

 

1,261

 

 

 

1,262

 

 

 

1,261

 

 

 

1,262

 

Cash dividends declared per share

 

$

0.73

 

 

$

0.71

 

 

$

2.19

 

 

$

2.13

 

 

 

 

 

 

 

 

 

 

Product gross margin

 

 

80.0

%

 

 

83.4

%

 

 

78.3

%

 

 

80.0

%

Research and development expenses as a % of revenues

 

 

16.3

%

 

 

14.8

%

 

 

17.2

%

 

 

16.2

%

Selling, general and administrative expenses as a % of revenues

 

 

17.2

%

 

 

16.0

%

 

 

18.4

%

 

 

17.9

%

Operating margin

 

 

40.3

%

 

 

51.8

%

 

 

25.5

%

 

 

44.8

%

Effective tax rate

 

 

26.6

%

 

 

24.8

%

 

 

22.5

%

 

 

22.5

%

GILEAD SCIENCES, INC.

TOTAL REVENUE SUMMARY

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Nine Months Ended

 

 

 

 

September 30,

 

 

 

September 30,

 

 

(in millions, except percentages)

 

2022

 

2021

 

Change

 

2022

 

2021

 

Change

Product sales:

 

 

 

 

 

 

 

 

 

 

 

 

HIV

 

$

4,487

 

$

4,189

 

7%

 

$

12,422

 

$

11,777

 

5%

HCV

 

 

524

 

 

429

 

22%

 

 

1,371

 

 

1,488

 

(8)%

HBV/HDV

 

 

264

 

 

247

 

7%

 

 

733

 

 

704

 

4%

Cell therapy

 

 

398

 

 

222

 

79%

 

 

1,040

 

 

632

 

65%

Trodelvy

 

 

180

 

 

101

 

78%

 

 

485

 

 

262

 

85%

Other

 

 

200

 

 

245

 

(18)%

 

 

693

 

 

777

 

(11)%

Total product sales excluding Veklury

 

 

6,053

 

 

5,433

 

11%

 

 

16,745

 

 

15,640

 

7%

Veklury

 

 

925

 

 

1,923

 

(52)%

 

 

2,905

 

 

4,208

 

(31)%

Total product sales

 

 

6,978

 

 

7,356

 

(5)%

 

 

19,650

 

 

19,848

 

(1)%

Royalty, contract and other revenues

 

 

64

 

 

65

 

(1)%

 

 

242

 

 

213

 

14%

Total revenues

 

$

7,042

 

$

7,421

 

(5)%

 

$

19,892

 

$

20,061

 

(1)%

GILEAD SCIENCES, INC.

NON-GAAP FINANCIAL INFORMATION(1)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

Nine Months Ended

 

 

 

 

September 30,

 

 

 

September 30,

 

 

(in millions, except percentages)

 

2022

 

2021

 

Change

 

2022

 

2021

 

Change

Non-GAAP:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

923

 

 

$

736

 

 

25%

 

$

2,634

 

 

$

2,427

 

 

9%

Research and development expenses

 

$

1,173

 

 

$

1,063

 

 

10%

 

$

3,425

 

 

$

3,149

 

 

9%

Acquired IPR&D expenses

 

$

448

 

 

$

65

 

 

NM

 

$

786

 

 

$

270

 

 

NM

Selling, general and administrative expenses

 

$

1,212

 

 

$

1,178

 

 

3%

 

$

3,566

 

 

$

3,332

 

 

7%

Other income (expense), net

 

$

20

 

 

$

(12

)

 

NM

 

$

25

 

 

$

(29

)

 

NM

Diluted EPS

 

$

1.90

 

 

$

2.65

 

 

(28)%

 

$

5.59

 

 

$

6.50

 

 

(14)%

 

 

 

 

 

 

 

 

 

 

 

 

 

Product gross margin

 

 

86.8

%

 

 

90.0

%

 

-323 bps

 

 

86.6

%

 

 

87.8

%

 

-121 bps

Research and development expenses as a % of revenues

 

 

16.7

%

 

 

14.3

%

 

236 bps

 

 

17.2

%

 

 

15.7

%

 

152 bps

Selling, general and administrative expenses as a % of revenues

 

 

17.2

%

 

 

15.9

%

 

131 bps

 

 

17.9

%

 

 

16.6

%

 

133 bps

Operating margin

 

 

46.7

%

 

 

59.0

%

 

-1234 bps

 

 

47.7

%

 

 

54.2

%

 

-654 bps

Effective tax rate

 

 

22.4

%

 

 

18.9

%

 

350 bps

 

 

20.1

%

 

 

18.9

%

 

120 bps

________________________________

NM - Not Meaningful

(1)

Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10 - 11. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission, the Company no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation.

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions, except percentages and per share amounts)

 

2022

 

2021

 

2022

 

2021

Cost of goods sold reconciliation:

 

 

 

 

 

 

 

 

GAAP cost of goods sold

 

$

1,395

 

 

$

1,223

 

 

$

4,261

 

 

$

3,974

 

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

(472

)

 

 

(487

)

 

 

(1,585

)

 

 

(1,547

)

Other(1)

 

 

 

 

 

 

 

 

(42

)

 

 

 

Non-GAAP cost of goods sold

 

$

923

 

 

$

736

 

 

$

2,634

 

 

$

2,427

 

 

 

 

 

 

 

 

 

 

Product gross margin reconciliation:

 

 

 

 

 

 

 

 

GAAP product gross margin

 

 

80.0

%

 

 

83.4

%

 

 

78.3

%

 

 

80.0

%

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

6.8

%

 

 

6.6

%

 

 

8.1

%

 

 

7.8

%

Other(1)

 

 

%

 

 

%

 

 

0.2

%

 

 

%

Non-GAAP product gross margin

 

 

86.8

%

 

 

90.0

%

 

 

86.6

%

 

 

87.8

%

 

 

 

 

 

 

 

 

 

Research and development expenses reconciliation:

 

 

 

 

 

 

 

 

GAAP research and development expenses

 

$

1,149

 

 

$

1,101

 

 

$

3,429

 

 

$

3,243

 

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

 

.

 

(67

)

 

 

 

 

 

(67

)

Acquisition-related – other costs(2)

 

 

24

 

 

 

(2

)

 

 

13

 

 

 

(14

)

Other(1)

 

 

 

 

 

31

 

 

 

(18

)

 

 

(13

)

Non-GAAP research and development expenses

 

$

1,173

 

 

$

1,063

 

 

$

3,425

 

 

$

3,149

 

 

 

 

 

 

 

 

 

 

IPR&D impairment reconciliation:

 

 

 

 

 

 

 

 

GAAP IPR&D impairment

 

$

 

 

$

 

 

$

2,700

 

 

$

 

IPR&D impairment

 

 

 

 

 

 

 

 

(2,700

)

 

 

 

Non-GAAP IPR&D impairment

 

$

 

 

$

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses reconciliation:

 

 

 

 

 

 

 

 

GAAP selling, general and administrative expenses

 

$

1,213

 

 

$

1,190

 

 

$

3,653

 

 

$

3,596

 

Acquisition-related – other costs(2)

 

 

(2

)

 

 

(10

)

 

 

(2

)

 

 

(42

)

Other(1)

 

 

1

 

 

 

(2

)

 

 

(84

)

 

 

(222

)

Non-GAAP selling, general and administrative expenses

 

$

1,212

 

 

$

1,178

 

 

$

3,566

 

 

$

3,332

 

 

 

 

 

 

 

 

 

 

Income from operations reconciliation:

 

 

 

 

 

 

 

 

GAAP income from operations

 

$

2,836

 

 

$

3,842

 

 

$

5,063

 

 

$

8,978

 

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

472

 

 

 

554

 

 

 

1,585

 

 

 

1,614

 

Acquisition-related – other costs(2)

 

 

(22

)

 

 

12

 

 

 

(11

)

 

 

56

 

IPR&D impairment

 

 

 

 

 

 

 

 

2,700

 

 

 

 

Other(1)

 

 

(1

)

 

 

(29

)

 

 

144

 

 

 

235

 

Non-GAAP income from operations

 

$

3,286

 

 

$

4,379

 

 

$

9,480

 

 

$

10,883

 

 

 

 

 

 

 

 

 

 

Operating margin reconciliation:

 

 

 

 

 

 

 

 

GAAP operating margin

 

 

40.3

%

 

 

51.8

%

 

 

25.5

%

 

 

44.8

%

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

6.7

%

 

 

7.5

%

 

 

8.0

%

 

 

8.0

%

Acquisition-related – other costs(2)

 

 

(0.3

)%

 

 

0.2

%

 

 

(0.1

)%

 

 

0.3

%

IPR&D impairment

 

 

%

 

 

%

 

 

13.6

%

 

 

%

Other(1)

 

 

%

 

 

(0.7

)%

 

 

0.7

%

 

 

1.1

%

Non-GAAP operating margin

 

 

46.7

%

 

 

59.0

%

 

 

47.7

%

 

 

54.2

%

 

 

 

 

 

 

 

 

 

Other income (expense), net reconciliation:

 

 

 

 

 

 

 

 

GAAP other income (expense), net

 

$

(176

)

 

$

(154

)

 

$

(571

)

 

$

(696

)

Loss from equity securities, net

 

 

197

 

 

 

142

 

 

 

596

 

 

 

667

 

Non-GAAP other income (expense), net

 

$

20

 

 

$

(12

)

 

$

25

 

 

$

(29

)

 

 

 

 

 

 

 

 

 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions, except percentages and per share amounts)

 

2022

 

2021

 

2022

 

2021

Effective tax rate reconciliation:

 

 

 

 

 

 

 

 

GAAP effective tax rate

 

 

26.6

%

 

 

24.8

%

 

 

22.5

%

 

 

22.5

%

Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(3)

 

 

(4.1

)%

 

 

(5.8

)%

 

 

(2.4

)%

 

 

(3.5

)%

Non-GAAP effective tax rate

 

 

22.4

%

 

 

18.9

%

 

 

20.1

%

 

 

18.9

%

 

 

 

 

 

 

 

 

 

Net income attributable to Gilead reconciliation:

 

 

 

 

 

 

 

 

GAAP net income attributable to Gilead

 

$

1,789

 

 

$

2,592

 

 

$

2,952

 

 

$

5,843

 

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

379

 

 

 

446

 

 

 

1,264

 

 

 

1,301

 

Acquisition-related – other costs(2)

 

 

(23

)

 

 

9

 

 

 

(13

)

 

 

46

 

IPR&D impairment

 

 

 

 

 

 

 

 

2,057

 

 

 

 

Other(1)

 

 

 

 

 

(23

)

 

 

104

 

 

 

143

 

Loss from equity securities, net

 

 

198

 

 

 

154

 

 

 

570

 

 

 

687

 

Discrete and related tax charges(3)

 

 

49

 

 

 

165

 

 

 

118

 

 

 

179

 

Non-GAAP net income attributable to Gilead

 

$

2,391

 

 

$

3,343

 

 

$

7,052

 

 

$

8,199

 

 

 

 

 

 

 

 

 

 

Diluted EPS reconciliation:

 

 

 

 

 

 

 

 

GAAP diluted EPS

 

$

1.42

 

 

$

2.05

 

 

$

2.34

 

 

$

4.63

 

Acquisition-related – amortization of acquired intangibles and inventory step-up charges

 

 

0.30

 

 

 

0.35

 

 

 

1.00

 

 

 

1.03

 

Acquisition-related – other costs(2)

 

 

(0.02

)

 

 

0.01

 

 

 

(0.01

)

 

 

0.04

 

IPR&D impairment

 

 

 

 

 

 

 

 

1.63

 

 

 

 

Other(1)

 

 

 

 

 

(0.01

)

 

 

0.08

 

 

 

0.12

 

Loss from equity securities, net

 

 

0.16

 

 

 

0.12

 

 

 

0.45

 

 

 

0.54

 

Discrete and related tax charges(3)

 

 

0.04

 

 

 

0.13

 

 

 

0.09

 

 

 

0.14

 

Non-GAAP diluted EPS

 

$

1.90

 

 

$

2.65

 

 

$

5.59

 

 

$

6.50

 

 

 

 

 

 

 

 

 

 

Non-GAAP adjustment summary:

 

 

 

 

 

 

 

 

Cost of goods sold adjustments

 

$

472

 

 

$

487

 

 

$

1,627

 

 

$

1,547

 

Research and development expenses adjustments

 

 

(24

)

 

 

38

 

 

 

5

 

 

 

94

 

IPR&D impairment adjustments

 

 

 

 

 

 

 

 

2,700

 

 

 

 

Selling, general and administrative expenses adjustments

 

 

1

 

 

 

12

 

 

 

86

 

 

 

264

 

Total non-GAAP adjustments before other income (expense), net, and income taxes

 

 

450

 

 

 

537

 

 

 

4,418

 

 

 

1,905

 

Other income (expense), net, adjustments

 

 

197

 

 

 

142

 

 

 

596

 

 

 

667

 

Total non-GAAP adjustments before income taxes

 

 

646

 

 

 

679

 

 

 

5,014

 

 

 

2,572

 

Income tax effect of non-GAAP adjustments above

 

 

(93

)

 

 

(93

)

 

 

(1,032

)

 

 

(395

)

Discrete and related tax charges(3)

 

 

49

 

 

 

165

 

 

 

118

 

 

 

179

 

Total non-GAAP adjustments after tax

 

$

602

 

 

$

751

 

 

$

4,100

 

 

$

2,356

 

______________________________

(1)

Adjustments to Cost of goods sold and Research and development expenses primarily include various restructuring expenses during the first quarter of 2022 and the second quarter of 2021. Adjustments to Selling, general and administrative expenses primarily include donations to the Gilead Foundation, a California nonprofit organization, during the second quarters of 2022 and 2021.

(2)

Adjustments include employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s acquisitions of MiroBio, Ltd., Immunomedics, Inc. and MYR GmbH.

(3)

Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2022 FULL-YEAR GUIDANCE(1)

(unaudited)

 

 

 

 

 

 

 

 

 

(in millions, except percentages and per share amounts)

 

Provided

February 1, 2022

 

Updated

April 28, 2022

 

Updated

August 2, 2022

 

Updated

October 27, 2022

Projected product gross margin GAAP to non-GAAP reconciliation:

 

 

 

 

 

 

 

 

GAAP projected product gross margin

 

76% - 77%

 

76% - 77%

 

76% - 77%

 

78% - 79%

Acquisition-related and other

 

~ 9%

 

~ 9%

 

~ 9%

 

~ 8%

Non-GAAP projected product gross margin

 

85% - 86%

 

85% - 86%

 

85% - 86%

 

86% - 87%

 

 

 

 

 

 

 

 

 

Projected income from operations GAAP to non-GAAP reconciliation:

 

 

 

 

 

 

 

 

GAAP projected income from operations

 

$8,600 - $9,400

 

$5,800 - $6,600

 

$6,050 - $6,650

 

$6,900 - $7,300

Acquisition-related, IPR&D impairment and other

 

~ 2,100

 

~ 4,900

 

~ 4,950

 

~ 4,900

Non-GAAP projected income from operations

 

$10,700 - $11,500

 

$10,700 - $11,500

 

$11,000 - $11,600

 

$11,800 - $12,200

 

 

 

 

 

 

 

 

 

Projected effective tax rate GAAP to non-GAAP reconciliation:

 

 

 

 

 

 

 

 

GAAP projected effective tax rate

 

~ 22%

 

~ 20%

 

~ 21%

 

~ 22%

Discrete and related tax adjustments, and income tax effect of adjustments above and fair value adjustments of equity securities

 

~ 2%

 

—%

 

~ 1%

 

~ 2%

Non-GAAP projected effective tax rate

 

~ 20%

 

~ 20%

 

~ 20%

 

~ 20%

 

 

 

 

 

 

 

 

 

Projected diluted EPS GAAP to non-GAAP reconciliation:

 

 

 

 

 

 

 

 

GAAP projected diluted EPS

 

$4.70 - $5.20

 

$3.00- $3.50

 

$2.90 - $3.30

 

$3.35 - $3.55

Acquisition-related, IPR&D impairment, fair value adjustments of equity securities, other and discrete and related tax adjustments

 

~ 1.50

 

~ 3.20

 

~ 3.45

 

~ 3.60

Non-GAAP projected diluted EPS

 

$6.20 - $6.70

 

$6.20 - $6.70

 

$6.35 - $6.75

 

$6.95 - $7.15

________________________________

(1)

The non-GAAP 2022 full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts.

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

 

 

 

 

 

 

September 30,

 

December 31,

(in millions)

 

2022

 

2021

Assets

 

 

 

 

Cash, cash equivalents and marketable securities

 

$

6,942

 

$

7,829

Accounts receivable, net

 

 

4,354

 

 

4,493

Inventories

 

 

2,602

 

 

2,734

Property, plant and equipment, net

 

 

5,349

 

 

5,121

Intangible assets, net

 

 

29,440

 

 

33,455

Goodwill

 

 

8,314

 

 

8,332

Other assets

 

 

5,556

 

 

5,988

Total assets

 

$

62,557

 

$

67,952

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities

 

$

10,423

 

$

11,610

Long-term liabilities

 

 

31,077

 

 

35,278

Stockholders’ equity(1)

 

 

21,057

 

 

21,064

Total liabilities and stockholders’ equity

 

$

62,557

 

$

67,952

________________________________

(1)

As of September 30, 2022 and December 31, 2021, there were 1,254 shares of common stock issued and outstanding, respectively.

GILEAD SCIENCES, INC.

SELECTED CASH FLOW INFORMATION

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions)

 

2022

 

2021

 

2022

 

2021

Net cash provided by operating activities

 

$

2,863

 

 

$

3,253

 

 

$

6,505

 

 

$

8,179

 

Net cash used in investing activities

 

 

(713

)

 

 

(234

)

 

 

(2,091

)

 

 

(2,853

)

Net cash used in financing activities

 

 

(2,118

)

 

 

(3,527

)

 

 

(4,915

)

 

 

(6,935

)

Effect of exchange rate changes on cash and cash equivalents

 

 

(72

)

 

 

(23

)

 

 

(138

)

 

 

(26

)

Net change in cash and cash equivalents

 

 

(40

)

 

 

(531

)

 

 

(639

)

 

 

(1,635

)

Cash and cash equivalents at beginning of period

 

 

4,739

 

 

 

4,893

 

 

 

5,338

 

 

 

5,997

 

Cash and cash equivalents at end of period

 

$

4,699

 

 

$

4,362

 

 

$

4,699

 

 

$

4,362

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions)

 

2022

 

2021

 

2022

 

2021

Net cash provided by operating activities

 

$

2,863

 

 

$

3,253

 

 

$

6,505

 

 

$

8,179

 

Capital expenditures

 

 

(157

)

 

 

(139

)

 

 

(547

)

 

 

(423

)

Free cash flow(1)

 

$

2,706

 

 

$

3,114

 

 

$

5,958

 

 

$

7,756

 

________________________________

(1)

Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions)

 

2022

 

2021

 

2022

 

2021

HIV

 

 

 

 

 

 

 

 

Biktarvy – U.S.

 

$

2,286

 

$

1,875

 

$

6,088

 

$

4,926

Biktarvy – Europe

 

 

278

 

 

254

 

 

807

 

 

707

Biktarvy – Other International

 

 

201

 

 

147

 

 

577

 

 

461

 

 

 

2,766

 

 

2,276

 

 

7,472

 

 

6,094

 

 

 

 

 

 

 

 

 

Complera / Eviplera – U.S.

 

 

20

 

 

28

 

 

56

 

 

73

Complera / Eviplera – Europe

 

 

21

 

 

31

 

 

76

 

 

104

Complera / Eviplera – Other International

 

 

3

 

 

5

 

 

10

 

 

12

 

 

 

43

 

 

64

 

 

142

 

 

189

 

 

 

 

 

 

 

 

 

Descovy – U.S.

 

 

444

 

 

355

 

 

1,152

 

 

994

Descovy – Europe

 

 

28

 

 

42

 

 

92

 

 

128

Descovy – Other International

 

 

28

 

 

36

 

 

91

 

 

105

 

 

 

500

 

 

433

 

 

1,335

 

 

1,227

 

 

 

 

 

 

 

 

 

Genvoya – U.S.

 

 

502

 

 

576

 

 

1,441

 

 

1,633

Genvoya – Europe

 

 

71

 

 

100

 

 

220

 

 

306

Genvoya – Other International

 

 

27

 

 

68

 

 

103

 

 

184

 

 

 

600

 

 

744

 

 

1,764

 

 

2,123

 

 

 

 

 

 

 

 

 

Odefsey – U.S.

 

 

276

 

 

275

 

 

763

 

 

773

Odefsey – Europe

 

 

86

 

 

112

 

 

278

 

 

336

Odefsey – Other International

 

 

12

 

 

12

 

 

36

 

 

39

 

 

 

374

 

 

399

 

 

1,077

 

 

1,148

 

 

 

 

 

 

 

 

 

Stribild – U.S.

 

 

22

 

 

28

 

 

68

 

 

94

Stribild – Europe

 

 

7

 

 

11

 

 

23

 

 

33

Stribild – Other International

 

 

3

 

 

3

 

 

7

 

 

12

 

 

 

32

 

 

42

 

 

98

 

 

139

 

 

 

 

 

 

 

 

 

Truvada – U.S.

 

 

24

 

 

55

 

 

77

 

 

268

Truvada – Europe

 

 

3

 

 

5

 

 

12

 

 

18

Truvada – Other International

 

 

2

 

 

7

 

 

13

 

 

24

 

 

 

30

 

 

67

 

 

102

 

 

310

 

 

 

 

 

 

 

 

 

Revenue share – Symtuza(1) – U.S.

 

 

85

 

 

86

 

 

251

 

 

261

Revenue share – Symtuza(1) – Europe

 

 

40

 

 

41

 

 

126

 

 

125

Revenue share – Symtuza(1) – Other International

 

 

4

 

 

3

 

 

10

 

 

8

 

 

 

130

 

 

130

 

 

388

 

 

394

 

 

 

 

 

 

 

 

 

Other HIV(2) – U.S.

 

 

1

 

 

24

 

 

11

 

 

110

Other HIV(2) – Europe

 

 

6

 

 

6

 

 

20

 

 

19

Other HIV(2) – Other International

 

 

5

 

 

4

 

 

15

 

 

24

 

 

 

12

 

 

34

 

 

45

 

 

153

 

 

 

 

 

 

 

 

 

Total HIV – U.S.

 

 

3,661

 

 

3,302

 

 

9,906

 

 

9,132

Total HIV – Europe

 

 

541

 

 

602

 

 

1,653

 

 

1,776

Total HIV – Other International

 

 

285

 

 

285

 

 

863

 

 

869

 

 

 

4,487

 

 

4,189

 

 

12,422

 

 

11,777

 

 

 

 

 

 

 

 

 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions)

 

2022

 

2021

 

2022

 

2021

Veklury

 

 

 

 

 

 

 

 

Veklury – U.S.

 

336

 

1,527

 

1,179

 

2,763

Veklury – Europe

 

130

 

109

 

560

 

761

Veklury – Other International

 

458

 

287

 

1,166

 

684

 

 

925

 

1,923

 

2,905

 

4,208

HCV

 

 

 

 

 

 

 

 

Ledipasvir / Sofosbuvir(3) – U.S.

 

8

 

14

 

27

 

63

Ledipasvir / Sofosbuvir(3) – Europe

 

5

 

5

 

13

 

24

Ledipasvir / Sofosbuvir(3) – Other International

 

12

 

26

 

43

 

76

 

 

25

 

45

 

83

 

163

 

 

 

 

 

 

 

 

 

Sofosbuvir / Velpatasvir(4) – U.S.

 

241

 

173

 

629

 

649

Sofosbuvir / Velpatasvir(4) – Europe

 

131

 

77

 

288

 

234

Sofosbuvir / Velpatasvir(4) – Other International

 

84

 

82

 

244

 

272

 

 

455

 

332

 

1,161

 

1,155

 

 

 

 

 

 

 

 

 

Other HCV(5) – U.S.

 

34

 

37

 

88

 

97

Other HCV(5) – Europe

 

7

 

12

 

31

 

64

Other HCV(5) – Other International

 

2

 

3

 

7

 

9

 

 

44

 

52

 

127

 

170

 

 

 

 

 

 

 

 

 

Total HCV – U.S.

 

283

 

224

 

745

 

809

Total HCV – Europe

 

143

 

94

 

332

 

322

Total HCV – Other International

 

98

 

111

 

294

 

357

 

 

524

 

429

 

1,371

 

1,488

HBV/HDV

 

 

 

 

 

 

 

 

Vemlidy – U.S.

 

129

 

103

 

306

 

266

Vemlidy – Europe

 

9

 

9

 

27

 

25

Vemlidy – Other International

 

90

 

96

 

289

 

298

 

 

228

 

208

 

622

 

589

 

 

 

 

 

 

 

 

 

Viread – U.S.

 

2

 

1

 

4

 

8

Viread – Europe

 

5

 

7

 

17

 

22

Viread – Other International

 

15

 

18

 

48

 

55

 

 

22

 

26

 

69

 

85

 

 

 

 

 

 

 

 

 

Other HBV/HDV(6) – U.S.

 

 

 

1

 

1

Other HBV/HDV(6) – Europe

 

13

 

13

 

41

 

29

 

 

14

 

13

 

42

 

30

 

 

 

 

 

 

 

 

 

Total HBV/HDV – U.S.

 

131

 

104

 

311

 

275

Total HBV/HDV – Europe

 

28

 

29

 

85

 

76

Total HBV/HDV – Other International

 

106

 

114

 

337

 

353

 

 

264

 

247

 

733

 

704

Cell therapy

 

 

 

 

 

 

 

 

Tecartus – U.S.

 

60

 

35

 

160

 

94

Tecartus – Europe

 

20

 

12

 

56

 

25

Tecartus – Other International

 

1

 

 

2

 

 

 

81

 

47

 

217

 

119

 

 

 

 

 

 

 

 

 

Yescarta – U.S.

 

210

 

100

 

528

 

300

Yescarta – Europe

 

91

 

66

 

253

 

188

Yescarta – Other International

 

16

 

9

 

42

 

25

 

 

317

 

175

 

823

 

513

 

 

 

 

 

 

 

 

 

Total cell therapy – U.S.

 

270

 

135

 

688

 

394

Total cell therapy – Europe

 

111

 

78

 

308

 

213

Total cell therapy – Other International

 

17

 

9

 

44

 

25

 

 

398

 

222

 

1,040

 

632

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

(in millions)

 

2022

 

2021

 

2022

 

2021

Trodelvy

 

 

 

 

 

 

 

 

Trodelvy – U.S.

 

 

139

 

 

100

 

 

379

 

 

261

Trodelvy– Europe

 

 

38

 

 

1

 

 

98

 

 

1

Trodelvy – Other International

 

 

3

 

 

 

 

8

 

 

 

 

 

180

 

 

101

 

 

485

 

 

262

Other

 

 

 

 

 

 

 

 

AmBisome – U.S.

 

 

9

 

 

7

 

 

48

 

 

32

AmBisome – Europe

 

 

63

 

 

67

 

 

192

 

 

202

AmBisome – Other International

 

 

33

 

 

69

 

 

140

 

 

186

 

 

 

105

 

 

143

 

 

380

 

 

420

 

 

 

 

 

 

 

 

 

Letairis – U.S.

 

 

43

 

 

46

 

 

135

 

 

157

 

 

 

 

 

 

 

 

 

Other(7) – U.S.

 

 

28

 

 

34

 

 

91

 

 

109

Other(7) – Europe

 

 

11

 

 

17

 

 

52

 

 

68

Other(7) – Other International

 

 

13

 

 

5

 

 

35

 

 

23

 

 

 

52

 

 

56

 

 

178

 

 

200

 

 

 

 

 

 

 

 

 

Total other – U.S.

 

 

80

 

 

87

 

 

275

 

 

298

Total other – Europe

 

 

75

 

 

84

 

 

244

 

 

270

Total other – Other International

 

 

46

 

 

74

 

 

174

 

 

209

 

 

 

200

 

 

245

 

 

693

 

 

777

 

 

 

 

 

 

 

 

 

Total product sales – U.S.

 

 

4,900

 

 

5,479

 

 

13,482

 

 

13,932

Total product sales – Europe

 

 

1,064

 

 

997

 

 

3,281

 

 

3,419

Total product sales – Other International

 

 

1,013

 

 

880

 

 

2,887

 

 

2,497

 

 

$

6,978

 

$

7,356

 

$

19,650

 

$

19,848

_______________________________

(1)

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2)

Includes Atripla, Emtriva and Tybost.

(3)

Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC.

(4)

Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC.

(5)

Includes Vosevi and Sovaldi.

(6)

Includes Hepcludex and Hepsera.

(7)

Includes Cayston, Jyseleca, Ranexa and Zydelig.

 

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.